|
1
|
Global Burden of Disease Cancer
Collaboration. Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, motality, years of
life lost, yeas lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ju DY, Hainaut P, Gores GJ, Amadou A,
Plymoth A and Roberts LR: A global view of hepatocellular
carcinoma: trends, risk, prevention and management. Nat Rev
Gastroenterol Hepatol. 16:589–604. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Choi YH and Yu AM: ABC transporters in
multidrug resistance and pharmacokinetics, and strategies for drug
development. Curr Pharm Des. 20:793–807. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Thomas C and Tampé R: Structural and
mechanistic principles of ABC transporters. Ann Rev Biochem.
89:605–636. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wang Y, Qin Z, Cai S, Yu L, Hu H and Zeng
S: The role of non-coding RNAs in ABC transporters regulation and
their clinical implications of multidrug resistance in cancer.
Expert Opin Drug Metab Toxicol. 17:291–306. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hegedus C, Telbisz A, Hegedus T, Sarkadi B
and Ozvegy-Laczka C: Lipid regulation of the ABCB1 and ABCG2
multidrug transporters. Adv Cancer Res. 125:97–137. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
To KK, Poon DC, Wei Y, Wang F, Lin G and
Fu LW: Vatalanib sensitizes ABCB1 and ABCG2-overexpressing
multidrug resistant colon cancer cells to chemotherapy under
hypoxia. Biochem Pharmacol. 97:27–37. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Limniatis G and Georges E: Down-regulation
of ABCB1 by collateral sensitivity drugs reverses multidrug
resistance and up-regulates enolase I. J Biochem. 172:37–48.
2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kukal S, Guin D, Rawat C, Bora S, Mishra
MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, et al:
Multidrug efflux transporter ABCG2: expression and regulation. Cell
Mol Life Sci. 78:6887–6939. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Xie ZY, Lv K, Xiong Y and Guo WH:
ABCG2-meditated multidrug resistance and tumor-initiating capacity
of side population cells from colon cancer. Oncol Res Treat.
37:666–668. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kozovska Z, Gabrisova V and Kucerova L:
Colon cancer: Cancer stem cells markers, drug resistance and
treatment. Biomed Pharmacother. 68:911–916. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen D: Tumor formation and drug
resistance properties of human glioblastoma side population cells.
Mol Med Rep. 11:4309–4314. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang M, Wang Y and Zhong J: Side
population cells and drug resistance in breast cancer. Mol Med Rep.
11:4297–4302. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kumar P, Nagarajan A and Uchil PD:
Analysis of cell viability by the MTT assay. Cold Spring Harb
Protoc. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Method. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Motlagh NS, Parvin P, Ghasemi F and Atyabi
F: . Fluorescence properties of several chemotherapy drugs:
Doxorubicin, paclitaxel and bleomycin. Biomed Opt Express.
25:2400–2406. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wu Q, Yang Z, Nie Y, Shi Y and Fan D:
Multi-drug resistance in cancer chemotherapeutics: mechanisms and
lab approaches. Cancer Lett. 347:159–166. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lu JF, Pokharel D and Bebawy M: MRP1 and
its role in anticancer drug resistance. Drug Metab Rev. 47:406–419.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Masanek U, Stammler G and Volm M:
Modulation of multidrug resistance in human ovarian cancer cell
lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with
antisense oligonucleotides. J Exp Ther Oncol. 2:37–41.
2002.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang YF, Li XH, Shi YQ, Wu YY, Li N, He
Q, Ji Q, Wang RQ, Yang SM and Fang DC: CIAPIN1 confers multidrug
resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr
cells and is independent of p53. Oncol Rep. 25:1091–1098.
2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lo YL, Wang W and Ho CT:
7,3',4'-Trihydroxyisoflavone modulates multidrug resistance
transporters and induces apoptosis via production of reactive
oxygen species. Toxicology. 302:221–232. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kunická T and Souček P: Importance of
ABCC1 for cancer therapy and prognosis. Drug Metab Rev. 46:325–342.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Misra R, Das M, Sahoo BS and Sahoo SK:
Reversal of multidrug resistance in vitro by co-delivery of MDR1
targeting siRNA and doxorubicin using a novel cationic
poly(lactide-co-glycolide) nanoformulation. Int J Pharm.
475:372–384. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hsieh MJ, Chen MK, Yu YY, Sheu GT and
Chiou HL: Psoralen reverses docetaxel-induced multidrug resistance
in A549/D16 human lung cancer cells lines. Phytomedicine.
21:970–977. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wu CP, Hsiao SH, Murakami M, Lu YJ, Li YQ,
Huang YH, Hung TH, Ambudkar SV and Wu YS: Alpha-mangostin reverses
multidrug resistance by attenuating the function of the multidrug
resistance-linked ABCG2 transporter. Mol Pharm. 14:2805–2814.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Murakami M, Ohnuma S, Fukuda M, Chufan EE,
Kudoh K, Kanehara K, Sugisawa N, Ishida M, Naitoh T, Shibata H, et
al: Synthetic analogs of curcumin modulate the function of
multidrug resistance-linked ATP-binding cassette transporter ABCG2.
Drug Metab Dispos. 45:1166–1177. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Fan YF, Zhang W, Zeng L, Lei ZN, Cai CY,
Gupta P, Yang DH, Cui Q, Qin ZD, Chen ZS and Trombetta LD:
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells
by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Cancer Lett. 421:186–198. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen Y, Bieber MM and Teng NN: Hedgehog
signaling regulates drug sensitivity by targeting ABC transporters
ABCB1 and ABCG2 in epithelial ovarian cancer. Mol Carcinog.
53:625–634. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Sodani K, Tiwari AK, Singh S, Patel A,
Xiao ZJ, Chen JJ, Sun YL, Talele TT and Chen ZS: GW583340 and
GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and
ABCB1-mediated drug resistance. Biochem Pharmacol. 83:1613–1622.
2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lepper ER, Nooter K, Verweij J, Acharya
MR, Figg WD and Sparreboom A: Mechanisms of resistance to
anticancer drugs: The role of the polymorphic ABC transporters
ABCB1 and ABCG2. Pharmacogenomics. 6:115–138. 2005.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sodani K, Patel A, Anreddy N, Singh S,
Yang DH, Kathawala RJ, Kumar P, Talele TT and Chen ZS: Telatinib
reverses chemotherapeutic multidrug resistance mediated by ABCG2
efflux transporter in vitro and in vivo. Biochem Pharmacol.
89:52–61. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Rosenfeldt MT, Bell LA, Long JS, O'Prey J,
Nixon C, Roberts F, Dufès C and Ryan KM: E2F1 drives
chemotherapeutic drug resistance via ABCG2. Oncogene. 33:4164–4172.
2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nakanishi T and Ross DD: Breast cancer
resistance protein (BCRP/ABCG2): Its role in multidrug resistance
and regulation of its gene expression. Chin J Cancer. 31:73–99.
2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yousaf M and Ali M: Modulation of ABCG2
surface expression by Rab5 and Rab21 to overcome multidrug
resistance in cancer cells. Xenobiotica. 50:988–996.
2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kokubo S, Ohnuma S, Murakami M, Kikuchi H,
Funayama S, Suzuki H, Kajiwara T, Yamamura A, Karasawa H, Sugisawa
N, et al: A phenylfurocoumarin derivative reverses ABCG2-mediated
multidrug resistance in vitro and in vivo. Int J Mol Sci.
22(12502)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Mioč M, Telbisz Á, Radman K, Bertoša B,
Šumanovac T, Sarkadi B and Kralj M: Interaction of crown ethers
with the ABCG2 transporter and their implication for multidrug
resistance reversal. Histochem Cell Biol. 158:261–277.
2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ma Y, Guo Z, Fan C, Chen J, Xu S and Liu
Z: Rationally screened and designed ABCG2-binding aptamers for
targeting cancer stem cells and reversing multidrug resistance.
Anal Chem. 94:7375–7382. 2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zattoni IF, Delabio LC, Dutra JP, Kita DH,
Scheiffer G, Hembecker M, Pereira GDS, Moure VR and Valdameri G:
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional
inhibitors and expression modulators. Eur J Med Chem.
237(114346)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhang QH, Dou HT, Xu P, Zhuang SC and Liu
PS: Tumor recurrence and drug resistance properties of side
population cells in high grade ovary cancer. Drug Res (Stuttg).
65:153–157. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Britton KM, Eyre R, Harvey IJ, Stemke-Hale
K, Browell D, Lennard TWJ and Meeson AP: . Breast cancer, side
population cells and ABCG2 expression. Cancer Lett. 323:97–105.
2012.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Tandia M, Mhiri A, Paule B, Saffroy R,
Cailliez V, Noé G, Farinotti R and Bonhomme-Faivre L: Correlation
between clinical response to sorafenib in hepatocellular carcinoma
treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast
cancer resistance protein (ABCG2): Monocentric study. Cancer
Chemother Pharmacol. 79:759–766. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhang H, Zhang YK, Wang YJ, Kathawala RJ,
Patel A, Zhu H, Sodani K, Talele TT, Ambudkar SV, Chen ZS and Fu
LW: WHI-P154 enhances the chemotherapeutic effect of anticancer
agents in ABCG2-overexpressing cells. Cancer Sci. 105:1071–1078.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wang XK, To KK, Huang LY, Xu JH, Yang K,
Wang F, Huang ZC, Ye S and Fu LW: Afatinib circumvents multidrug
resistance via dually inhibiting ATP binding cassette subfamily G
member 2 in vitro and in vivo. Oncotarget. 5:11971–11985.
2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan
YY, Wang F, Chen ZS, Tong XZ and Fu LW: Sensitization of
ABCG2-overexpressing cells to conventional chemotherapeutic agent
by sunitinib was associated with inhibiting the function of ABCG2.
Cancer Lett. 279:74–83. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Jing W, Zhou M, Chen R, Ye X, Li W, Su X,
Luo J, Wang Z and Peng S: In vitro and ex vivo
anti-tumor effect and mechanism of Tucatinib in leukemia stem cells
and ABCG2-overexpressing leukemia cells. Oncol Rep. 45:1142–1152.
2021.PubMed/NCBI View Article : Google Scholar
|
